A phase III registrational trial of LUM-201 in Children With Growth Hormone Deficiency
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Ibutamoren (Primary)
- Indications Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Sponsors Lumos Pharma
- 01 Aug 2024 According to a Lumos Pharma media release, company expects to be in a position to initiate this trial in the second quarter of 2025
- 14 May 2024 According to a Lumos Pharma media release, End of Phase 2 Meeting Held with FDA, FDA indicated that a placebo-controlled trial design is an appropriate option for a Phase 3 trial for LUM-201.
- 14 May 2024 According to a Lumos Pharma media release, company expects to initiate a Phase 3 trial of LUM-201 in Q4 2024, subject to FDA approval.